Company Description
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology.
The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect.
The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
| Country | United States |
| IPO Date | Jun 21, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 377 |
| CEO | John P. Shannon |
Contact Details
Address: 180 North LaSalle Street Chicago, Illinois United States | |
| Website | https://www.xerispharma.com |
Stock Details
| Ticker Symbol | XERS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001867096 |
| CUSIP Number | 98422E103 |
| ISIN Number | US98422E1038 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John P. Shannon | Chief Executive Officer & Director |
| Beth P. Hecht J.D. | Chief Legal Officer & Corporate Secretary |
| Steven M. Pieper | Chief Financial Officer |
| Allison Wey | Senior Vice President of Investor Relations & Corporate Communications |
| Brian Conner | SVice President of Quality and Chief Compliance & Risk Officer |
| Dr. Kenneth E. Johnson Pharm. D., Pharm.D. | Senior Vice President of Global Development & Medical Affairs |
| Kendal Korte | Senior Vice President of Human Resources |
| Kevin McCulloch | Chief Commercial Officer |
| Paul R. Edick J.D. | Senior Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 26, 2024 | 4 | Filing |
| Nov 08, 2024 | 10-Q | Quarterly Report |
| Nov 08, 2024 | 8-K | Current Report |
| Aug 13, 2024 | 4 | Filing |
| Aug 12, 2024 | 4 | Filing |
| Aug 09, 2024 | 4 | Filing |
| Aug 09, 2024 | 4 | Filing |
| Aug 09, 2024 | 4 | Filing |
| Aug 08, 2024 | S-8 | Filing |
| Aug 08, 2024 | 10-Q | Quarterly Report |